|
2021-07-20 |
2021-07-19 |
V
Vente
|
Muzikant Adam
Chief Business Officer
Dirigeant
|
1 870
-1.8%
6,45
12 062 USD
|
1 870
-1.8%
|
6,45
|
12 062 USD
|
|
|
2021-05-12 |
2021-05-10 |
V
Vente
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
2 229
-1.0%
7,23
16 116 USD
|
2 229
-1.0%
|
7,23
|
16 116 USD
|
|
|
2021-03-16 |
2021-03-15 |
V
Vente
|
Layman Melissa
Chief Commercial Officer
Dirigeant
|
4 520
-4.2%
11,80
53 336 USD
|
4 520
-4.2%
|
11,80
|
53 336 USD
|
|
|
2021-01-29 |
2021-01-28 |
V
Vente
|
Layman Melissa
Chief Commercial Officer
Dirigeant
|
2 624
-2.9%
12,55
32 931 USD
|
2 624
-2.9%
|
12,55
|
32 931 USD
|
|
|
2021-01-07 |
2021-01-05 |
VP
Vente planifiée
|
KELLEY SCOTT
Chief Medical Officer
Dirigeant
|
6 829
-5.7%
11,13
76 007 USD
|
6 829
-5.7%
|
11,13
|
76 007 USD
|
|
|
2021-01-07 |
2021-01-05 |
VP
Vente planifiée
|
Wentworth Kerry
Chief Regulatory Officer
Dirigeant
|
6 829
-5.7%
11,13
76 007 USD
|
6 829
-5.7%
|
11,13
|
76 007 USD
|
|
|
2021-01-07 |
2021-01-05 |
V
Vente
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
6 073
-3.9%
11,13
67 592 USD
|
6 073
-3.9%
|
11,13
|
67 592 USD
|
|
|
2021-01-07 |
2021-01-05 |
V
Vente
|
Muzikant Adam
Chief Business Officer
Dirigeant
|
4 005
-5.2%
11,13
44 576 USD
|
4 005
-5.2%
|
11,13
|
44 576 USD
|
|
|
2021-01-07 |
2021-01-05 |
V
Vente
|
Levine Mark S.
General Counsel
Dirigeant
|
6 829
-6.0%
11,13
76 007 USD
|
6 829
-6.0%
|
11,13
|
76 007 USD
|
|
|
2021-01-07 |
2021-01-05 |
V
Vente
|
Willwerth Christina
Chief Strategy Officer
Dirigeant
|
6 602
-5.4%
11,13
73 480 USD
|
6 602
-5.4%
|
11,13
|
73 480 USD
|
|
|
2020-05-27 |
2020-05-26 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
10 256
+3.0%
9,75
99 996 USD
|
10 256
+3.0%
|
9,75
|
99 996 USD
|
|
|
2020-05-27 |
2020-05-26 |
A
Achat
|
Stejbach Mark
Administrateur non-exécutif
|
2 051
+inf%
9,75
19 997 USD
|
2 051
+inf%
|
9,75
|
19 997 USD
|
|
|
2020-05-11 |
2020-05-07 |
VP
Vente planifiée
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
2 413
-2.0%
10,88
26 253 USD
|
2 413
-2.0%
|
10,88
|
26 253 USD
|
|
|
2020-01-07 |
2020-01-03 |
V
Vente
|
KELLEY SCOTT
Chief Medical Officer
|
3 724
0,00
0 USD
|
3 724
|
0,00
|
0 USD
|
|
|
2020-01-07 |
2020-01-03 |
VP
Vente planifiée
|
Levine Mark S.
General Counsel
|
3 724
0,00
0 USD
|
3 724
|
0,00
|
0 USD
|
|
|
2020-01-07 |
2020-01-03 |
V
Vente
|
Arkowitz David
Chief Financial Officer
|
3 095
0,00
0 USD
|
3 095
|
0,00
|
0 USD
|
|
|
2020-01-07 |
2020-01-03 |
VP
Vente planifiée
|
Wentworth Kerry
Chief Regulatory Officer
|
3 724
0,00
0 USD
|
3 724
|
0,00
|
0 USD
|
|
|
2020-01-07 |
2020-01-03 |
V
Vente
|
Bodick Neil
Chief Scientific Officer
|
3 851
0,00
0 USD
|
3 851
|
0,00
|
0 USD
|
|
|
2020-01-07 |
2020-01-03 |
V
Vente
|
Willwerth Christina
Chief Strategy Officer
|
3 533
0,00
0 USD
|
3 533
|
0,00
|
0 USD
|
|
|
2019-08-09 |
2019-08-08 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
2 000
+4.6%
10,74
21 480 USD
|
2 000
+4.6%
|
10,74
|
21 480 USD
|
|
|
2019-08-08 |
2019-08-08 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
2 317
+3.3%
10,85
25 136 USD
|
2 317
+3.3%
|
10,85
|
25 136 USD
|
|
|
2019-06-03 |
2019-05-31 |
A
Achat
|
Arkowitz David
Chief Financial Officer
|
2 500
+2.9%
11,05
27 627 USD
|
2 500
+2.9%
|
11,05
|
27 627 USD
|
|
|
2019-05-24 |
2019-05-23 |
A
Achat
|
MERRIFIELD C ANN
Administrateur non-exécutif
|
8 000
+400.0%
12,64
101 120 USD
|
8 000
+400.0%
|
12,64
|
101 120 USD
|
|
|
2019-05-15 |
2019-05-13 |
A
Achat
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
4 000
+4.8%
11,99
47 960 USD
|
4 000
+4.8%
|
11,99
|
47 960 USD
|
|
|
2019-05-13 |
2019-05-10 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
4 012
+5.7%
12,48
50 067 USD
|
4 012
+5.7%
|
12,48
|
50 067 USD
|
|
|
2019-05-09 |
2019-05-08 |
VP
Vente planifiée
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
2 248
-2.6%
10,06
22 615 USD
|
2 248
-2.6%
|
10,06
|
22 615 USD
|
|
|
2019-03-13 |
2019-03-12 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
4 046
+6.1%
12,36
50 009 USD
|
4 046
+6.1%
|
12,36
|
50 009 USD
|
|
|
2019-01-04 |
2019-01-03 |
VP
Vente planifiée
|
Bodick Neil
Chief Scientific Officer
Dirigeant
|
746
-1.1%
12,36
9 221 USD
|
746
-1.1%
|
12,36
|
9 221 USD
|
|
|
2019-01-04 |
2019-01-03 |
VP
Vente planifiée
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
3 278
-4.7%
12,36
40 516 USD
|
3 278
-4.7%
|
12,36
|
40 516 USD
|
|
|
2019-01-04 |
2019-01-03 |
VP
Vente planifiée
|
Levine Mark S.
General Counsel
Dirigeant
|
734
-7.5%
12,36
9 072 USD
|
734
-7.5%
|
12,36
|
9 072 USD
|
|
|
2019-01-04 |
2019-01-03 |
VP
Vente planifiée
|
Wentworth Kerry
Chief Regulatory Officer
Dirigeant
|
622
-5.3%
12,36
7 688 USD
|
622
-5.3%
|
12,36
|
7 688 USD
|
|
|
2019-01-04 |
2019-01-03 |
VP
Vente planifiée
|
KELLEY SCOTT
Chief Medical Officer
Dirigeant
|
622
-3.9%
12,36
7 688 USD
|
622
-3.9%
|
12,36
|
7 688 USD
|
|
|
2018-11-13 |
2018-11-09 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
5 000
+7.8%
17,10
85 477 USD
|
5 000
+7.8%
|
17,10
|
85 477 USD
|
|
|
2018-11-13 |
2018-11-09 |
A
Achat
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
4 000
+9.0%
16,56
66 222 USD
|
4 000
+9.0%
|
16,56
|
66 222 USD
|
|
|
2018-08-10 |
2018-08-09 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
10 000
+15.3%
22,33
223 300 USD
|
10 000
+15.3%
|
22,33
|
223 300 USD
|
|
|
2018-08-10 |
2018-08-09 |
A
Achat
|
Arkowitz David
Chief Financial Officer
Dirigeant
|
4 000
+9.9%
23,42
93 680 USD
|
4 000
+9.9%
|
23,42
|
93 680 USD
|
|
|
2018-07-03 |
2018-07-03 |
VP
Vente planifiée
|
Bodick Neil
Chief Scientific Officer
Dirigeant
|
16 492
-20.9%
25,00
412 300 USD
|
16 492
-20.9%
|
25,00
|
412 300 USD
|
|
|
2018-07-03 |
2018-07-02 |
VP
Vente planifiée
|
Bodick Neil
Chief Scientific Officer
Dirigeant
|
33 508
-29.8%
25,10
841 192 USD
|
33 508
-29.8%
|
25,10
|
841 192 USD
|
|
|
2017-11-22 |
2017-11-21 |
A
Achat
|
Bodick Neil
Chief Scientific Officer
|
1 000
+inf%
24,66
24 656 USD
|
1 000
+inf%
|
24,66
|
24 656 USD
|
|
|
2017-11-22 |
2017-11-21 |
A
Achat
|
Bodick Neil
Chief Scientific Officer
|
1 700
+2.7%
24,39
41 457 USD
|
1 700
+2.7%
|
24,39
|
41 457 USD
|
|
|
2017-11-09 |
2017-11-08 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
5 000
+16.5%
23,60
118 000 USD
|
5 000
+16.5%
|
23,60
|
118 000 USD
|
|
|
2017-09-15 |
2017-09-05 |
A
Achat
|
Deniz Yamo
Chief Medical Officer
|
1 000
+12.5%
24,20
24 200 USD
|
1 000
+12.5%
|
24,20
|
24 200 USD
|
|
|
2017-09-15 |
2017-09-01 |
A
Achat
|
Deniz Yamo
Chief Medical Officer
|
2 000
+33.3%
23,95
47 900 USD
|
2 000
+33.3%
|
23,95
|
47 900 USD
|
|
|
2017-09-15 |
2017-09-01 |
A
Achat
|
Deniz Yamo
Chief Medical Officer
|
1 000
+20.0%
24,55
24 550 USD
|
1 000
+20.0%
|
24,55
|
24 550 USD
|
|
|
2017-09-15 |
2017-08-31 |
A
Achat
|
Deniz Yamo
Chief Medical Officer
|
1 375
+37.9%
25,40
34 925 USD
|
1 375
+37.9%
|
25,40
|
34 925 USD
|
|
|
2017-06-20 |
2017-06-16 |
A
Achat
|
Stejbach Mark
|
1 580
+inf%
17,02
26 888 USD
|
1 580
+inf%
|
17,02
|
26 888 USD
|
|
|
2017-06-06 |
2017-06-05 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
5 000
+33.0%
17,23
86 152 USD
|
5 000
+33.0%
|
17,23
|
86 152 USD
|
|
|
2017-06-06 |
2017-06-05 |
A
Achat
|
COLELLA SAMUEL D
Actionnaire important
|
5 000
+inf%
17,01
85 048 USD
|
5 000
+inf%
|
17,01
|
85 048 USD
|
|
|
2017-05-17 |
2017-05-15 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
Dirigeant
|
1 700
-4.2%
19,39
32 967 USD
|
1 700
-4.2%
|
19,39
|
32 967 USD
|
|
|
2017-05-17 |
2017-05-15 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
Dirigeant
|
5 130
-11.2%
18,81
96 481 USD
|
5 130
-11.2%
|
18,81
|
96 481 USD
|
|
|
2017-04-18 |
2017-04-17 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
|
200
-0.4%
28,86
5 772 USD
|
200
-0.4%
|
28,86
|
5 772 USD
|
|
|
2017-04-18 |
2017-04-17 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
|
4 800
-9.4%
28,20
135 360 USD
|
4 800
-9.4%
|
28,20
|
135 360 USD
|
|
|
2017-03-24 |
2017-03-23 |
VP
Vente planifiée
|
DRISCOLL FREDERICK W
Chief Financial Officer
Dirigeant
|
3 000
-27.8%
23,00
69 000 USD
|
3 000
-27.8%
|
23,00
|
69 000 USD
|
|
|
2017-03-20 |
2017-03-17 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
|
5 000
-8.9%
20,41
102 039 USD
|
5 000
-8.9%
|
20,41
|
102 039 USD
|
|
|
2017-03-02 |
2017-02-28 |
VP
Vente planifiée
|
DRISCOLL FREDERICK W
Chief Financial Officer
Dirigeant
|
600
-7.2%
20,42
12 250 USD
|
600
-7.2%
|
20,42
|
12 250 USD
|
|
|
2017-03-02 |
2017-02-28 |
VP
Vente planifiée
|
DRISCOLL FREDERICK W
Chief Financial Officer
Dirigeant
|
32 834
-79.7%
19,96
655 429 USD
|
32 834
-79.7%
|
19,96
|
655 429 USD
|
|
|
2017-02-27 |
2017-02-24 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
|
5 000
-8.2%
19,15
95 758 USD
|
5 000
-8.2%
|
19,15
|
95 758 USD
|
|
|
2017-01-23 |
2017-01-20 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
|
5 000
-7.6%
18,35
91 747 USD
|
5 000
-7.6%
|
18,35
|
91 747 USD
|
|
|
2016-12-22 |
2016-12-21 |
VP
Vente planifiée
|
Bodick Neil
Chief Medical Officer
Dirigeant
|
10 000
-13.2%
18,46
184 628 USD
|
10 000
-13.2%
|
18,46
|
184 628 USD
|
|
|
2016-12-05 |
2016-12-01 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
10 000
+30.0%
16,38
163 807 USD
|
10 000
+30.0%
|
16,38
|
163 807 USD
|
|
|
2016-11-23 |
2016-11-23 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
1 667
+5.7%
18,41
30 688 USD
|
1 667
+5.7%
|
18,41
|
30 688 USD
|
|
|
2016-11-23 |
2016-11-22 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
1 666
+6.1%
17,95
29 900 USD
|
1 666
+6.1%
|
17,95
|
29 900 USD
|
|
|
2016-11-22 |
2016-11-21 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
33 333
+inf%
18,00
599 994 USD
|
33 333
+inf%
|
18,00
|
599 994 USD
|
|
|
2016-11-22 |
2016-11-21 |
A
Achat
|
Clayman Michael D.
President and CEO
Administrateur exécutif
|
1 666
+6.5%
17,90
29 827 USD
|
1 666
+6.5%
|
17,90
|
29 827 USD
|
|
|
2016-06-22 |
2016-06-21 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
400
+1.6%
13,71
5 483 USD
|
400
+1.6%
|
13,71
|
5 483 USD
|
|
|
2016-06-22 |
2016-06-21 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
504
+2.0%
13,65
6 881 USD
|
504
+2.0%
|
13,65
|
6 881 USD
|
|
|
2016-06-22 |
2016-06-21 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
4 600
+23.0%
13,76
63 288 USD
|
4 600
+23.0%
|
13,76
|
63 288 USD
|
|
|
2016-06-22 |
2016-06-21 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
13 222
+195.1%
13,62
180 114 USD
|
13 222
+195.1%
|
13,62
|
180 114 USD
|
|
|
2016-06-22 |
2016-06-20 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
3 343
+97.3%
13,70
45 813 USD
|
3 343
+97.3%
|
13,70
|
45 813 USD
|
|
|
2016-06-22 |
2016-06-20 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
3 435
+inf%
13,98
48 020 USD
|
3 435
+inf%
|
13,98
|
48 020 USD
|
|
|
2016-06-16 |
2016-06-14 |
A
Achat
|
MERRIFIELD C ANN
Administrateur non-exécutif
|
1 000
+100.0%
13,39
13 387 USD
|
1 000
+100.0%
|
13,39
|
13 387 USD
|
|
|
2016-06-10 |
2016-06-08 |
A
Achat
|
LUBASH BARBARA N
Actionnaire important
|
4 194
+25.3%
14,00
58 716 USD
|
4 194
+25.3%
|
14,00
|
58 716 USD
|
|
|
2016-06-10 |
2016-06-08 |
A
Achat
|
COLELLA SAMUEL D
Administrateur non-exécutif
Actionnaire important
|
4 194
+25.3%
14,00
58 716 USD
|
4 194
+25.3%
|
14,00
|
58 716 USD
|
|
|
2016-06-10 |
2016-06-08 |
A
Achat
|
Versant Ventures III, LLC
Actionnaire important
|
4 194
+25.3%
14,00
58 716 USD
|
4 194
+25.3%
|
14,00
|
58 716 USD
|
|
|
2016-06-10 |
2016-06-08 |
A
Achat
|
LUBASH BARBARA N
Actionnaire important
|
710 091
+25.3%
14,00
9 941 274 USD
|
710 091
+25.3%
|
14,00
|
9 941 274 USD
|
|
